Endocr Pract. 2017 Apr 2;23(4):451-457. doi: 10.4158/EP161632.OR. Epub 2017 Jan 17.
Encapsulated non-invasive follicular variant papillary thyroid cancer (ENIFVPTC) has recently been retermed noninvasive follicular thyroid neoplasm with papillary-like nuclear features (NIFTP). This designation specifically omits the word "cancer" to encourage conservative treatment since patients with NIFTP tumors have been shown to derive no benefit from completion thyroidectomy or adjuvant radio-active iodine (RAI) therapy.
This was a retrospective study of consecutive cases of tumors from 2007 to 2015 that met pathologic criteria for NIFTP. The conservative management (CM) group included patients managed with lobectomy alone or appropriately indicated total thyroidectomy. Those included in the aggressive management (AM) group received either completion thyroidectomy or RAI or both.
From 100 consecutive cases of ENIFVPTC reviewed, 40 NIFTP were included for the final analysis. Of these, 10 (27%) patients treated with initial lobectomy received completion thyroidectomy and 6 of 40 (16%) also received postsurgical adjuvant RAI. The mean per-patient cost of care in the AM group was $17,629 ± 2,865, nearly twice the $8,637 ± 309 costs in the CM group, and was largely driven by the cost of completion thyroidectomy and RAI.
The term NIFTP has been recently promulgated to identify a type of thyroid neoplasm, formerly identified as a low-grade cancer, for which initial surgery represents adequate treatment. We believe that since the new NIFTP nomenclature intentionally omits the word "cancer," the clinical indolence of these tumors will be better appreciated, and cost savings will result from more conservative and appropriate clinical management.
AM = aggressive management CM = conservative management ENIFVPTC = encapsulated noninvasive form of FVPTC FVPTC = follicular variant of papillary thyroid carcinoma NIFTP = noninvasive follicular thyroid neoplasm with papillary-like nuclear features PTC = papillary thyroid carcinoma PTMC = papillary thyroid microcarcinoma RAI = radio-active iodine US = ultrasound.
包裹性非侵袭性滤泡状甲状腺癌(ENIFVPTC)最近被重新命名为具有滤泡状甲状腺肿瘤伴乳头状核特征的非侵袭性滤泡性甲状腺肿瘤(NIFTP)。这一命名特别省略了“癌症”一词,以鼓励采用保守治疗,因为研究表明,NIFTP 肿瘤患者从甲状腺全切除术或辅助放射性碘(RAI)治疗中获益甚微。
这是一项回顾性研究,连续纳入 2007 年至 2015 年间符合 NIFTP 病理标准的肿瘤病例。保守治疗(CM)组包括接受单纯叶切除术或适当的甲状腺全切除术的患者。侵袭性治疗(AM)组包括接受甲状腺全切除术或 RAI 或两者联合治疗的患者。
在回顾的 100 例连续 ENIFVPTC 病例中,最终纳入 40 例 NIFTP 进行分析。其中,10 例(27%)初始行叶切除术的患者接受了甲状腺全切除术,40 例中有 6 例(16%)也接受了术后辅助 RAI。AM 组每位患者的平均治疗费用为 17629 美元±2865 美元,几乎是 CM 组 8637 美元±309 美元的两倍,主要由甲状腺全切除术和 RAI 的费用驱动。
最近提出了 NIFTP 一词,用于识别一种以前被确定为低级别癌症的甲状腺肿瘤类型,对于这种肿瘤,初始手术即可作为充分的治疗手段。我们认为,由于新的 NIFTP 命名法故意省略了“癌症”一词,人们将更好地认识到这些肿瘤的临床惰性,从而通过更保守和适当的临床管理节省成本。
AM = 侵袭性治疗 CM = 保守治疗 ENIFVPTC = 包裹性非侵袭性滤泡状甲状腺癌 FVPTC = 滤泡状甲状腺癌的滤泡变异型 NIFTP = 具有滤泡状甲状腺肿瘤伴乳头状核特征的非侵袭性滤泡性甲状腺肿瘤 PTC = 甲状腺乳头状癌 PTMC = 甲状腺微小乳头状癌 RAI = 放射性碘 US = 超声。